Parkinson's Disease Clinical Trials in Chicago

Showing 101-120 of 160 trials

PharmacoMRI of Parkinson Disease

NCT01528592

Based on studies showing better responsiveness of motor versus cognitive symptoms to Parkinson's Disease medication, also known as dopaminergic treatments, the investigators hypothesize that comparison of resting state networks in the on versus off medication state in Parkinson's Disease patients will show greater effects on brain networks associated with motor control.

Parkinson's Disease

Northwestern University18 participantsStarted Jun 2011

Chicago, Illinois, United States

COMPLETEDPhase 32.2 miles

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

NCT00105521

The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.

Parkinson's DiseaseDyskinesia

EMD Serono398 participantsStarted Sep 2004

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +29 more locations

PharmacoMRI of Parkinson Disease

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

Parkinson's Disease Trials in Other Cities

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

Pioglitazone in Early Parkinson's Disease

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

DNS-7801 vs. Placebo in Parkinson's Disease

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease

Caffeine as a Therapy for Parkinson's Disease

Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Remote Access to Care, Everywhere, for Parkinson Disease

Other Conditions in Chicago